[
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors",
    "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=a8ce5fb7ea1162ee004f282813f60c15898e1704386ec1990353d94f1984d02a",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734626760,
      "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors",
      "id": 132150453,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=a8ce5fb7ea1162ee004f282813f60c15898e1704386ec1990353d94f1984d02a"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron says study data support big bet on new blood thinners",
    "summary": "The company is planning a “broad Phase 3 program” for two anticoagulants after they outperformed marketed medicines in a pair of mid-stage trials.",
    "url": "https://finnhub.io/api/news?id=0faa2c53e0f18a9d99ec4aee5815834635d4b6d51c51253cbfb304fd67dcdf8b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734610980,
      "headline": "Regeneron says study data support big bet on new blood thinners",
      "id": 132056473,
      "image": "https://imgproxy.divecdn.com/TwlYIvz4kqzATt4hfGSlnnRyHXlkqu5n3XsDpGGZMws/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMjk3MDM0MzI5LmpwZw==.webp",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The company is planning a “broad Phase 3 program” for two anticoagulants after they outperformed marketed medicines in a pair of mid-stage trials.",
      "url": "https://finnhub.io/api/news?id=0faa2c53e0f18a9d99ec4aee5815834635d4b6d51c51253cbfb304fd67dcdf8b"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results",
    "summary": "Investigational REGN7508 (catalytic domain) and REGN9933 (A2 domain) are being evaluated for their potential to control thrombosis while minimizing bleeding risk in a variety of patient populations and clinical settings Evaluated against current standards of care, single doses of REGN7508 and REGN9933 administered 12 to 24 hours after total knee replacement demonstrated robust antithrombotic effects Phase 3 program to be initiated in 2025 TARRYTOWN, N.Y., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Regene",
    "url": "https://finnhub.io/api/news?id=44a503d6a2647834a2001d2afa3eb7c1fc7d938bf3e96a457fe8ea1f16c25abd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734609600,
      "headline": "Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results",
      "id": 132056474,
      "image": "",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Investigational REGN7508 (catalytic domain) and REGN9933 (A2 domain) are being evaluated for their potential to control thrombosis while minimizing bleeding risk in a variety of patient populations and clinical settings Evaluated against current standards of care, single doses of REGN7508 and REGN9933 administered 12 to 24 hours after total knee replacement demonstrated robust antithrombotic effects Phase 3 program to be initiated in 2025 TARRYTOWN, N.Y., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Regene",
      "url": "https://finnhub.io/api/news?id=44a503d6a2647834a2001d2afa3eb7c1fc7d938bf3e96a457fe8ea1f16c25abd"
    }
  }
]